Friday, 22 August 2014
Last updated 26 min ago
Mar 23 2010 | 12:20pm ET
To prevent a third proxy battle with Carl Icahn in three years, biotechnology company Biogen Idec has agreed to give the activist hedge fund manager a third seat on its board of directors.
Under the deal with Icahn, cancer specialist Eric Rowinsky will join Biogen’s board, alongside Alexander Denner, managing director of Icahn Partners, and Harvard Medical School genetics professor Richard Mulligan, Icahn nominees elected to the board last year.
For his part, Icahn has agreed to withdraw his three nominees to the board this year and the hedge fund will vote its shares for the management slate.
Aug 4 2014 | 7:42am ET
By now, U.S. and international subscribers have received their home or office delivery of the special 500th issue of Futures magazine. You can too!—a very special offer follows. The issue is the largest in years—filled with the best trading strategies and stories from 43 years of being the primary publication for commodity, stock, options and forex traders. Read more…
The July/August 2014 issue is our largest in years—filled with the best trading strategies and stories from 43 years of being the primary publication for commodity, stock, options and forex traders.
The Alpha Pages Editor's Note